Research output: Contribution to journal › Article › peer-review
Julie Fox, Michael Brady, Hannah Alexander, Olubanke Davies, Nicola Robinson, Mathew Pace, Laura Else, John Cason, Saye Khoo, David Back, Sarah Fidler, John Frater
| Original language | English |
|---|---|
| Pages (from-to) | 65-71 |
| Number of pages | 7 |
| Journal | Infectious diseases and therapy |
| Volume | 5 |
| Issue number | 1 |
| Early online date | 9 Jan 2016 |
| DOIs | |
| E-pub ahead of print | 9 Jan 2016 |
| Published | Mar 2016 |
Tenofovir Disoproxil Fumarate_FOX First online 9Jan2016 GOLD FPV
Tenofovir_Disoproxil_Fumarate_FOX_First_online_9Jan2016_GOLD_FPV.pdf, 430 KB, application/pdf
Uploaded date:25 May 2016
Version:Final published version
Licence:CC BY
The use of antiretrovirals as pre-exposure prophylaxis (PrEP) is highly efficacious in HIV prevention. The World Health Organization recently recommended Truvada(®) (Gilead Sciences, Inc.) or tenofovir disoproxil fumarate (TDF) for high-risk individuals, with limited data for single-agent TDF PrEP in men who have sex with men (MSM). We report two cases of TDF PrEP failure in MSM who had received long-term TDF for hepatitis B infection and had therapeutic levels of drug immediately after HIV acquisition. Rapid antiretroviral intensification at diagnosis of acute HIV infection failed to limit immune dysfunction or prevent the establishment of a viral reservoir.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454